Oppenheimer analyst Jay Olson maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $55 to $60.
According to TipRanks data, the analyst has a success rate of 39.0% and a total average return of 12.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
The initial Phase 1 data from RMC-9805 in patients with advanced pancreatic ductal adenocarcinoma presented at the EORTC-NCI-AACR Symposium bolstered the outlook for the ongoing second-line PDAC Phase 3 study of RMC-6036. The updated Phase 1/1b data that was shared last week has increased confidence in the potential success of the study.
Following recent clinical updates on '6236 and '9805 in PDAC, and an investor event, there is a positive outlook on the potential of '6236 in second line or later PDAC treatment, as the latest Phase 1 data indicated an enhanced median overall survival. Furthermore, initial data from the first-in-human trials of '9805 in PDAC has shown promising signs of clinical efficacy and an acceptable safety profile, exceeding initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
